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 We calculated the total cases of deterioration 











 Virtual Reality exposure therapy seems to be a non-
deleterious treatment  
 Participants are less probable to deteriorate in 
Virtual Reality and other active treatments than 
waiting list groups   
 Low deterioration rates prevent from establishing 




Ample evidence supports the use of Virtual Reality (VR) for anxiety disorders. Nonetheless, 
currently there is no evidence about moderators or potential negative effects of VR treatment 
strategies. An Individual Patient Data (IPD) approach was employed with 15 retrieved datasets. 
The current study sample was composed of 810 patients. Randomized control trials (RCTs) for 
each primary outcome measure were performed, in addition to moderator analyses of the socio-
demographic variables. Deterioration rates were 14 patients (4.0%) in VR, 8 (2.8%) in active 
control conditions, and 27 (15%) in the WL condition. With regard to receiving treatment, 
patients in a waiting list control condition had greater odds of deteriorating than in the two 
active conditions, odds ratios (ORs) 4.87, 95% confidence interval (CI) [0.05, 0.67]. In the case 
of the socio-demographic variables, none of them were associated with higher or lower odds of 
deterioration, with the exception of marital status in the WL condition; married people 
presented a significantly lower probability of deterioration, OR 0.19, 95% CI [0.05, 0.67]. 
Finally, when comparing pooled effects of VR versus all control conditions, the OR was 0.61 
(95% CI 0.31–1.23) in favor of VR, although this result was not statistically significant. This 
study provides evidence about the deterioration rates of a therapeutic VR approach, showing 
that the number of deteriorated patients coincides with other therapeutic approaches, and that 
deterioration is less likely to occur, compared to patients in WL control groups. 
 
















It has been well established that psychological treatments are effective for 
different existing clinical conditions comprised under the umbrella of anxiety disorders 
(Emmelkamp & Ehring, 2014). They include social anxiety disorders (Hofmann & 
DiBartolo, 2014), generalized anxiety disorder (Cuijpers, Sijbrandij, Koole, Huibers, 
Berking, & Andersson, 2014), panic disorder and agoraphobia (Pompoli et al., 2016), 
specific phobias (Wolitzky-Taylor, Horowitz, Powers, & Telch, 2008), and stress-related 
disorders, such as post-traumatic stress disorder (Cusack et al., 2016). 
 
However, the majority of this evidence is based on results of efficacy and face-to-face 
approaches. That is, conducting randomized control trials in non-naturalistic settings, 
which principally are tested in classical modalities in which one therapist attends one 
person. In this regard, the number of studies carried out in the past 20 years within the 
field of virtual reality (VR) has signified a great leap forward in incorporating 
technological advancements into psychological treatments. Indeed, VR is an illustrative 
example of how the potential of traditional face-to-face approaches can be enhanced, 
coinciding with what Kazdin and Blase described as rebooting psychotherapy (2011).  
 
A large body of evidence has shown the wide range of advantages of the use of VR for the 
treatment of anxiety disorders, including more ecological, personalized, and controlled 
assessments and interventions, an increase in the acceptability of treatments, and, 
consequently, greater adherence (Botella, 1998; Lindner et al., 2017; Riva, 2005). Hence, 
VR has become a widely-used tool to provide patients with less invasive, and in some 
cases more powerful, interventions for a wide range of psychopathological conditions 
(Botella et al., 2017). Anxiety disorders, and particularly specific phobias, have become 
paradigmatic in VR implementation because exposure is undoubtedly the main specific 
element that must be addressed; VR provides the ability to increase exposure (Bouchard & 
Wiederhold, 2014; Morina, Ijntema, Meyerbröker, & Emmelkamp, 2015; Opris et al., 2012; 
Powers & Emmelkamp, 2008). 
 
 
1.1 The unwanted shall not be avoided  
Although all the aforementioned evidence undoubtedly supports the efficacy of VR-based 
treatments for anxiety disorders, agreeing with the clinical scientific tradition, there has 
been a long-standing bias toward showing what is effective instead of recognizing possible 
negative effects (Barlow, 2010; Castonguay et al., 2010). In fact, a systematic review 
investigating the extent to which harm was reported in randomized control trials in 
clinical psychology indicated that only 21% of the analyzed trials reported harm on a 
patient level, and only 3% explicitly described procedures to analyze harmful treatments 
(Jonsson, Alaie, Parling, & Arnberg, 2014).  
 
This is a major challenge that has been undermined by the research, and, therefore, 
clinicians rightly perceive a lack of tools and mechanisms to measure, prevent, and deal 
with negative effects (Bystedt, Rozental, Andersson, Boettcher, & Carlbring, 2014; 
Peterson, Roache, Raj, & Young-McCaughan, 2013). Moreover, negative effects not only 
consist of iatrogenic effects and the vast array of worsening effects that a treatment can 
entail, but also the fact that a patient may not experience any benefits from a psychological 
treatment. For several reasons, an inert therapeutic process can be understood as a 
negative effect because it can make the patient more treatment resistant, create negative 
treatment expectations in the future, and increase the economic costs for the healthcare 













1.2 New promising trend  
Although there has been some sporadic research on negative effects from the 1960s 
onward (Bergin, 1963; Mohr, 1995; Strupp & Hadley, 1977), only in the past fifteen years 
has this topic sparked an interest within the fields of psychotherapy and clinical 
psychology. Illustrative examples are studies focused on operationalizing the concept of 
negative effects, which has led to creating a more accurate taxonomy of the intervening 
variables and the different subtypes that are assumed to occur during treatment (Linden & 
Schermurly-Haupt, 2014; Parry, Crawford, & Duggan, 2016).  
While it may be true that no clear consensus exists over the classification of negative 
effects, Linden (2013) presented a thorough examination of the topic, in which seven 
types of side effects were described in relation to a checklist. First, unwanted events (UE) 
are defined as all kind of negative effect that occur at any moment of treatment; 
treatment-emergent reaction is conceived as an UE provoked by the treatment; adverse 
treatment reaction is any UE probably caused by a correctly administered treatment; 
malpractice reaction is understood as the consequence of an improperly applied 
treatment; treatment non-response is the lack of improvement throughout a therapeutic 
process; deterioration of illness, which is conceptualized as a worsening in symptoms at 
any moment during or after treatment; therapeutic risk, that is, the known adverse 
treatment reactions that a treatment can entail; and contraindications.  
In addition, assessing each of the abovementioned aspects can be done in different ways. 
For instance, there are diverse areas to look for those negative effects, such as the 
appearance of novel symptoms, the deterioration of the existing symptoms, the decrease 
of social relationships and functioning, the dependency in the relationship with the 
therapist, among others.  
Furthermore, several self-report measures have been developed over the years (e.g. 
Hatfield et al., 2010; Ladwig, Rief, & Nestoriuc, 2014). Among the developed instruments 
are, for instance, the Vanderbilt Negative Indicator Scale (VNIS; Suh, Strupp, & O’Malley, 
1986), the Inventory for the Assessment of Negative Effects in Psychotherapy (INEP; 
Ladwig, Rief, & Nestoriuc, 2014) the Unwanted Events and Adverse Treatment Reaction 
Checklist for Psychotherapy (UE-ATR; Linden, 2013), the Experience of Therapy 
Questionnaire (ETQ; Parker, Fletcher, & Berk, 2013) and the Negative Effects 
Questionnaire (NEQ; Rozental, Kottorp, Boettcher, Andersson, & Carlbring, 2016). 
However, as explained in detail by Rozental and colleagues (2016), each scale has its own 
theoretical background as well as strengths and weaknesses. For example, the VNIS was 
based on a solid theory, but lacked practical utility given its comprehensive rating system. 
Similarly, the UE-ATR was proposed as a tool to help therapists detect negative effects, but 
was never intended to be used as a scale with psychometric properties. Moreover, the ETQ 
and the INEP both enjoys stronger empirical support, but the former includes items of 
both positive and negative nature, while the latter is comprised of items that are more 
related to malpractice than negative effects of properly implemented treatments.   
 
Another important advancement with regard to negative effects has been the study of 
trajectories of change during treatment. In this vein, a key issue has been the increasing 
incorporation of routine outcome monitoring via algorithms to identify patterns of 
deterioration that therapists may not detect using clinical judgement alone. This technique 
has been used successfully in both research and clinical settings as a way of tracking 
patients throughout treatment in order to prevent trajectories of worsening (Lambert & 
Shimokawa, 2011; Lutz, de Jong, & Rubel 2015; Whipple & Lambert, 2011). In this 
direction, a number of tools, such as the Outcome Questionnaire 45 (Lambert et al., 2004), 
CORE-OM (Barkham et al., 2001), Treatment Outcome Package (Kraus, Seligman, & Jordan, 
2005) or the PCOMS (Miller, Duncan, Sorrell, & Brown, 2005) among others, have been 
developed (for a discussion on the topic see Boswell, Kraus, Miller, & Lambert, 2015). In 
addition, both quantitative (e.g. Nordberg, Castonguay, McAleavey, Locke, & Hayes, 2016) 











outcome monitoring as a more objective way of determining how the patients are 
progressing through the therapeutic process.  
A further development that has permitted to better determine the nature of negative 
trajectories has been the conceptualization of sudden losses within psychotherapy 
treatments. Sudden losses derived from the reverse concept of sudden gains that have 
been extensively researched (Tang & DeRubeis, 1999) and is therefore conceptualized as a 
significant worsening between two sessions. It has been identified as a marker of possible 
treatment failure (Lutz et al., 2013).  
Finally, alliance ruptures, that is, a breakdown in the therapeutic relationship, not only is a 
relevant phenomenon to understand the trajectory of change but also as a key moment 
that may be taken to greatly improve the therapeutic outcomes by means of its repair 
(Safran, Muran, & Eubanks-Carter, 2011). Table 1 summarizes all the mentioned types of 
negative effects.  
 
 
Table 1 Types of negative effects and assessment tools 
Negative effects Main target Assessment tool 
 
 





General approaches to 
assess different facets of a 
treatment that directly or 
indirectly provoked a 
negative effect. 
Unwanted Events and Adverse Treatment Reaction Checklist 
for Psychotherapy (Linden, 2013) 
Inventory for the Assessment of Negative Effects in 
Psychotherapy (Ladwig et al., 2014) 
Experience of Therapy Questionnaire (Parker et al., 2013) 
Vanderbilt Negative Indicator (Suh et al., 1986) 
Negative Effects Questionnaire (Rozental et al., 2016) 
Sudden losses Identifying significant 
worsening processes 
between two sessions 





OQ-45 (Lambert et al., 2004); CORE-OM (Barkham et al., 
2001); TOP (Kraus et al., 2005); PCOMS (Miller et al., 2005) 
Alliance Ruptures Detecting breakdown in 
the therapeutic 
relationship  




1.3 Negative effects in technology-mediated treatments 
In a context where the implementation of technology is increasing exponentially in clinical 
research and practice (e.g. Botella et al., 2012; Imel et al., 2017; Mohr, Weingardt, Reddy, & 
Schueller, 2017; Riva, 2005), negative effects should be further explored. Internet-based 
interventions are a positive exception to the rule because, due to the novelty of the 
approach, a considerable number of studies have been conducted (Carlbring, Andersson, 
Cuijpers, Riper., & Hedman-Lagerlöf, In press). Diverse qualitative endeavors have focused 
on the patients’ experiences of negative effects (Rozental, Boettcher, Andersson, Schmidt, 











or dropout experiences (Fernández-Álvarez et al., 2017). Recently, three high quality 
individual patient data (IPD) meta-analyses were published that assessed deterioration 
rates in Internet interventions (Ebert et al., 2017; Karyotaki et al., 2018; Rozental, 
Magnusson, Boettcher, Andersson, & Carlbring, 2017).  
However, other domains within the technology-mediated realm have not explored the 
negative effects of the therapeutic processes. VR is a paradigmatic example because it 
emerged more than 20 years ago as a treatment option for different psychological 
disorders; however, very few studies have focused on the possible negative effects of the 
treatments. In the first years of the use of VR as a therapeutic tool, there was concern 
about possible negative effects that the technology could introduce, such as an effect on 
reality judgment, especially for severe mental disorders like schizophrenia (Baños, Botella, 
& Perpiña, 1999; Rizzo, Wiederhold, & Buckwalter, 1998). One decade later, other 
theoretical studies pointed out the need to take this topic into account (Botella, García-
Palacios, Baños, Gregg & Tarrier, 2007); however, no empirical study has yet focused on 
the potential negative effects that might exist. The only exception is a study of a PTSD 
treatment that mentioned possible worsening due to the exposure. The assessed domains 
were in relation to risk of suicide and alcohol consumption, so it was not deterioration of 
the post-traumatic symptoms but exacerbation of other side effects (Beidel, Frueh & Rizzo, 
2014).  In addition, although not related to treatment outcomes, studies have explored 
more physiological side effects of using technological devices, which has been labeled 
cybersickness (Rebenitsch & Owen, 2015).  
Given the scarcity of empirical studies on the negative effects of VR-based treatments, and 
the fact that the use of VR is expected to significantly increase due to emerging affordable 
models (e.g. Gear VR and Google Cardboard), it is time to explore the possible deleterious 
effects of VR-based treatments.  
 
 
1.4 The current study 
The main goal of the present study was to examine the deterioration rates in the existing 
randomized control trials for anxiety disorders conducted with VR. Among the different 
available options to assess negative effects, deterioration rates have been proposed as the 
most straightforward method to capture the phenomenon. While other ways of assessing 
negative effects can be of great clinical value, like the subjective experience of the 
participants or a decrease in interpersonal functioning, a through quantitative study is 
difficult given the lack of specific scales adapted to VR and the complex nature of the 
intervening variables (Rozental et al., 2017). Deterioration can be defined as a worsening 
in symptomatology, and given that the outcomes of treatment are always investigated in 
randomized control trials, the procedure for exploring the number of patients who are 






Adults diagnosed with an anxiety disorder (including those categorized as anxiety 
disorders in the DSM-IV, e.g., PTSD and OCD) who received a manualized treatment that 
included VR and an active condition or a waiting list as control to the VR condition were 
eligible for inclusion. By validated protocol is meant a manualized treatment   The VR 
condition had to have at least 10 patients, following the cut-off point identified by 
Meyerbröker and Emmelkamp (2010). Only papers published in peer-reviewed journals in 
English, Spanish, German, or Italian were considered for inclusion. Retrieved data also had 
to include values for the primary outcome measure for each individual patient because the 












2.2. Data items 
P: adult population with anxiety disorders or stress related disorders 
I: psychological intervention with VR1  
C: non-VR active condition or waiting list 
O: symptomatology 
S: randomized control trials 
 
 
2.2 Search strategy 
First, through a systematic search of Pubmed and Web of Science, two reviewers 
independently searched potentially relevant articles. There was no restriction on the year 
of publication, and the last update of the search strings was carried out in March 2017. For 
every database consultation, specific keywords and mesh terms were used (see appendix 
1 for the string used for Pubmed). In all cases, our strings consisted of two components: 
(1) virtual reality and all synonyms; and (2) anxiety disorders and all related and specific 
terms.  
Supplementary strategies were also applied. One involved manual searches of literature 
reviews and book chapters and their reference lists. The other involved examining 
references of all the included articles; relevant excluded articles were also manually 
examined.  
 
2.4 Study selection process 
All the articles were exported to Mendeley. The overall search yielded 1272 records, of 
which 646 were retrieved for further examination after eliminating duplicates. In the next 
step, the two reviewers independently read all the titles, removing all titles that were not 
relevant to the purpose of the systematic review (e.g. did not mention VR or related terms, 
or were not based on psychological interventions). There were no discrepancies between 
the two reviewers. After this step, 124 full-text articles were considered potentially 
relevant studies. Finally, 36 studies were found eligible according to the eligibility criteria.  
 
2.5 Studies included in the IPD meta-analysis 
Unlike standard meta-analyses, after systematically reviewing the existing literature on 
VR-based trials, all of the datasets were requested. From the obtained datasets, a new 
dataset was created with the aim of assessing the raw scores for each patient in order to 
achieve a more accurate examination, rather than one based on group means and standard 
deviations. In the case of deterioration rates, the individual patient level approach is the 
only way to determine their occurrence; these are the effects that were meta-analyzed.     
 
The last author of this paper used email to contact all the corresponding authors of the 36 
papers included. This e-mail contained the purpose of the study, and corresponding 
authors were invited to participate in the manuscript as co-authors, given the major 
contribution they were making by sharing the data.  
Finally, 15 studies were included for the data analysis, as 21 datasets could not be 
retrieved from the authors for different reasons, including irretrievable data, impossibility 
of sharing the material due to legal constraints, or no answer from the corresponding 
authors (after 3 attempts)2. Figure 1 presents a flow chart of the systematic review.  
 
                                                 
1 One study was conducted with Augmented Reality (Botella et al., 2016), but because it lies on the mixed reality continuum, 














































Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Diagram 
of selected studies. 
 
2.6 Quality Assessment of included studies 
To assess the risk of bias, the Cochrane Handbook for Systematic Review Interventions 
(Higgins et al., 2011) was used. The following domains were assessed: (1) Random 
sequence generation and allocation concealment (selection bias); (2) Therapist and 
researcher allegiance, treatment fidelity (performance bias); (3) Blinding of outcome 
assessor (detection bias); (4) Incomplete outcome data reporting (attrition bias); and (5) 
Selective outcome reporting (reporting bias). We assessed and categorized the risk of bias 
following the Cochrane guidelines: (1) low risk of bias, plausible bias unlikely to seriously 
alter the results; (2) high risk of bias, plausible bias that seriously weakens confidence in 
the results; and (3) unclear risk of bias, plausible bias that raises some doubt about the 
results. Two independent reviewers screened the studies, with discrepancies being 
resolved by consensus. Overall, 92.22% agreement was reached in the initial independent 
review.  
 
2.7 Statistical analysis 
Deterioration was determined using the Reliable Change Index (RCI), following the 
recommendations given by Jacobson, Follette, and Revenstorf (1984). The RCI reflects 
whether a change score between two measurement points is reliable and not caused 
solely by measurement error. For the current study, it was used to assess a reliable 
deterioration. In the IPD meta-analysis, the RCI was calculated by subtracting the scores 











dividing the difference by the standard error of difference between the two test scores 
(Evans, Marginson, & Barkham, 1998). This was done separately for each clinical trial 
because they used different primary outcome measures, and the RCI is affected by the 
different standard deviations at pretreatment assessment. Furthermore, the standard 
error of difference was derived from the test-retest reliabilities previously obtained for 
each primary outcome measure (see Table 2). This strategy is preferred over 
implementing internal consistencies, e.g., Cronbach’s α, as the test-retest reliability also 
introduces some variability between the two test scores (Speer, 1992). However, if there 
was more than one reliability estimate, as in the case of different subscales in the same 
self-report measure, the highest value was selected. In addition, for the Attitudes Towards 
Agoraphobia Questionnaire (North, North, & Coble, 1996), it was not possible to attain a 
reliability estimate; thus, instead it was derived from the Agoraphobia Inventory 
(Echeburúa et al., 1992). Moreover, on one of the clinical trials, García-Palacios et al. 
(2002), only the Behavioral Approach Test was administered as a measure of treatment 
outcome. Because this test cannot be used when assessing deterioration with the RCI, this 
study was removed from the analysis. 
 
Usually, an RCI of 1.96 is considered a reliable change (p = .05). However, Wise (2004) 
defended the use of a less conservative threshold to examine moderate and mild 
deterioration and improvement. This lowers the confidence levels, but could be important 
in identifying cases of worsening that might otherwise be overlooked. In addition, because 
the average rate of deterioration was quite low overall, with only about 5-10% faring 
worse during the treatment period (Lambert, 2013), capturing mild deterioration could 
increase the power for subsequent predictor analyses (Edwards et al., 1978). Therefore, in 
the IPD meta-analysis, an RCI of 0.84 was selected (p = .20). The same procedure was 
recently used by Rozental et al. (2017) in a similar IPD meta-analysis of deterioration in 
Internet-based cognitive behavior therapy. 
 
Patients exceeding an RCI of 0.84 in a negative direction were dummy coded as being 
reliably deteriorated (1 = yes, 0 = no). This information was later used to investigate 
possible predictors of worsening, using deterioration as the dependent variable in a 
logistic regression that implemented forced entry, i.e., all predictors were entered 
simultaneously. The independent variables, i.e., predictors, were chosen a priori: 1) 
clinical severity at pre-treatment assessment, 2) marital status, 3) educational level, 4) 
age, and 5) gender. This is a replication of the study by Rozental et al. (2017), except for 
prior psychological treatment, current use of psychotropic medication, and sick leave, as 
information about these aspects was not available in the current study. The results of the 
logistic regression are presented as odds ratios (OR), which refers to an increase or 
decrease in the odds of deterioration, compared to a predetermined reference category. 
For nominal variables, e.g., gender, the OR indicates an increase in the odds of worsening 
when going from female (0) to male (1) (see Table 6). For the continuous variables, i.e., 
clinical severity at pre-treatment assessment and age, the OR stands for an increase of 1 
SD above the mean. Predictors with an OR where the 95% Confidence Interval (CI) does 
not contain 1 are considered significant, which implies that they might predict 
deterioration. However, as with all analyses of predictors, the results should be 
considered tentative, requiring further research before any firm conclusions can be drawn 
about their importance (Clarke, 2005). Lastly, because there is a risk of ceiling effects 
when determining deterioration during treatment using self-report measures, scoring 
near the instrument’s maximum at pretreatment assessment was assessed by dummy 
coding of patients who were within the RCI’s upper boundary on each respective clinical 












Finally, to summarize the evidence obtained from the included studies, deterioration rates 
from VR group and a combination of deterioration rates from both control groups3 were 
used to calculate Odds Ratios (ORs). The summary statistic is reported as an OR with a CI 
of 95%. Heterogeneity was calculated with the Q statistic and the I2 index (Higgins, 
Thompson, Deeks, & Altman, 2003). The I2 index is interpreted as the percentage of 
between-study variance that is not explained by random sampling error of the primary 
studies. In other words, this index makes it possible to establish whether the variability is 
due to differences in the effect sizes or not (Borenstein et al., 2009). The percentages are 
used to discriminate low (25%), middle (50%), and high heterogeneity (75%). However, it 
must be taken into account that the I2 statistic can be biased when it is calculated based 
on small sample sizes (von Hippel, 2015). Given the ORs obtained, a forest plot was also 
prepared. This analysis was conducted using Comprehensive Meta-analysis software 
(Comprehensive Meta-Analysis, 2013). The odds ratio comparing the likelihood of 
deterioration between VR and waitlist was calculated using the MH method. Most 
commonly used meta-analytic approaches are based on assumptions that rely on large 
samples and may be inappropriate for assessment of rare events such as deterioration. 
The Mantel–Haenszel (MH) method has been shown to have minimal bias under 




2.9 Ethical considerations 
All the raw data are part of published studies approved by the respective ethical review 
boards. For more information, see the original studies. All the patients were coded so that 
they were unidentifiable within the new dataset created. In line with the description 
provided by Rozental et al. (2017), the present study utilized only the raw scores from 
already completed RCTs, making it impossible to intervene in those cases where 
deterioration was detected. However, the current study will hopefully encourage future 
RCTs to include a deterioration rate assessment, or other ways of determining potential 











Fear of Negative Evaluation Scale r = 0.75 4 weeks Normal Leary et al. (1983) 
Fear and Avoidance Scale r = 0.85 1 weeks  Patient Marks & Mathews (1979) 
Liebowitz Social Anxiety Scale – Self-Report r = 0.93 8 weeks Normal Heeren et al. (2012) 
Attitudes Towards Agoraphobia Questionnaire r = 0.69a 6 weeks Patient n.a. 
                                                 
3 This has been done to obtain only one funnel plot and retrieve more data (there were groups with no deterioration rates in one 











Clinician Administered PTSD Scale r = 0.96      - Patient Blake et al. (1995) 
Panic Disorder Severity Scale r = 0.94 2 days Patient Lee, Kim, & Yu (2009) 
Agoraphobia Inventory r = 0.69 6 weeks Patient 
Echeburúa, Corral, García, Páez, & Borda 
(1992)  
Fear of Flying Scale r = 0.94 12 weeks Patient Haug et al. (1987) 
Acrophobia Questionnaire r = 0.86 12 weeks Patient Baker, Cohen, & Saunders (1973) 
Flight Anxiety Situation Questionnaire r = 0.92        - Patient 
Van Gerwen, Spinhoven, Van Dyck, & 
Diekstra (1999) 
n.a. = not available 





3.1. Study characteristics 
The 36 studies that were eligible to meet all the inclusion criteria are presented in Table 3. 
After contacting corresponding authors of the published articles, datasets from 15 of these 
36 studies were retrieved (for the whole procedure, see 2.5.). Raw scores from these 
studies were aggregated into a unified dataset totaling 810 patients. Of this total number, 
348 (42.96%) received a VR treatment, 282 (34.81%) received other active treatment, and 
180 (22.22%) were in a waiting list condition. Regarding the clinical conditions, 230 
patients were diagnosed with social anxiety disorder (4 studies), 60 with agoraphobia (4 
studies), 17 with panic disorder (1 study), 225 with specific phobias including small 
animal phobias (2 studies) and fear of flying (4 studies), and 80 with post-traumatic stress 
disorder (3 studies)4.   
 
Analyzing the 36 papers, the only two studies that included deterioration rate analysis 
were Botella et al. (2016) and Reger et al. (2016). From a total sample of 162 patients, 
only 1 was deteriorated (in the VR condition). Other studies indicate the reliable change 
(e.g. Kampmann et al., 2016), but they do not report the deterioration rates.  
 
3.2. Representativeness of the included studies in relation to the 36 papers that met the 
criteria in the systematic review 
A total of 1956 patients with anxiety disorders treated with VR met the inclusion criteria 
specified for this study. This means that the recruited sample for the IPD analysis 
represents 41.10% of the overall sample. In terms of the clinical conditions, 22.43% of the 
PTSD patients, 23.66% of PD patients, 73.83% of AG patients, 21.09% of SP patients, and 
65.07% of SAD patients treated with VR were included in the analyses.  
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Post: (1 = 2) > 
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-1: VRET (n=20) 
-2: IET (n=10) 
8 SUDS Post: 1 > 2 Unspecified 
Note: F = Feminine; M = Masculine; EGT = Exposure Group Therapy; WL = Waiting List; FOF = Fear Of Flying; PRCS = Self-Report Of Public Speaking Fears; 
FNE-B = Self-Report Of Social Anxiety Disorder Symptoms; AGS = Augmented Reality System; BAT = Behavioural Avoidance Test ; SAD = Social Anxiety 
Disorder; PTSD = Post Traumatic Stress Disorder; PG= Pathological Grief; AD = Adjustment Disorders; PD = Panic Disorder; CBT+VR = Cognitive Behavioural 
Therapy Plus Virtual Reality; LSAS-SR = Liebowitz Social Anxiety Scale-Self Report; VRET = Virtual Reality Exposure Therapy; iVET = In Vivo Exposure 
Therapy; PANAS = Positive And Negative Affect Schedule; DASS = Depression Anxiety Stress Scale; ASI = Anxiety Sensitivity Index; CGI = Clinician Global 
Impression; MS = Maladjustment Scale; PBQ = Panic Belief Questionnaire; CAPS = Virtual Reality Exposure Therapy For The Treatment Of Posttraumatic Stress 
Disorder; BSI = Brief Symptom Inventory; MIA = Mobility Inventory For Agoraphobia; ACQ = Agoraphobic Cognitions Questionnaire; BSQ = Body Sensations 
Questionnaire; PDSS = Panic Disorder Severity Scale; FAS = Flight Anxiety Situations; AQ = Acrophobia Questionnaire; FAM = Flight Anxiety Modality; STAI = 
State And Trait Anxiety Questionnaire; SPSS = Self Statements During  Public Speaking Scale; FQ = Fear Questionnaire; REBT Theory = Rational Emotive 
Behaviour Therapy; CAS = Chambless Agoraphobic Cognitions; PPGAS = Panic, Phobia And Generalized Anxiety Scale; HAR S = Hamilton Anxiety Rating Scale; 
BDI = Beck Depression Inventory; WSA = Work And Social Adjustment Scale ;SDS = Sheehan Disability Scale; BAI = Beck Anxiety Inventory; SUA = Subjective 











BIB=Bibliotherapy; CAE-T = Computer-Aided Exposure With A Therapist’s; CAE-SA = Self-Administered Computer-Aided Exposure; IET = Imaginal Exposure 
Therapy; ATHQ= Attitude Towards Heights Questionnaire; FSQ= Fear of Spiders Questionnaire; HAD = Hospital Anxiety And Depression; SCIA = Social Contexts 
Inducing Anxiety; APGT= Attention Placebo Group Treatment; TAU = Treatment As Usual; SBQ-F = Spider Beliefs Questionnaire; SSPS = Self Statements During 
Public Speaking Scale; FFS = Fear Of Flying Scale; AFA = General Fear Of Flying Questionnaire (Allgemeiner Flugangstfragebogen); DES= Danger Expectancy 
Scale; AES = Anxiety Expectancy Scale; ATAQ = Attitude Towards Agoraphobia Questionnaire; SUDS = Subjective Units Of Discomfort Scale; AGPH = 
Agoraphobia Questionnaire;  FFI = Fear Of Flying Inventory; QAF = Questionnaire On Attitudes Toward Flying, FFQ = Fear Of Flying Questionnaire; ADIS-IV = 
Anxiety Disorders Interview Schedule For DSM-IV; MA = Minimal Attention control condition; PDS = PTSD Diagnostic Scale; QOLI = Quality of Life Inventory; 
TRGI = Trauma-Related Guilt Inventory; PCL-C = PTSD Checklist; SSRPH = Stigma Scale for Receiving Psychological Help; IASMHS = Inventory of Attitudes 
toward Seeking Mental Health Services; PE = Prolonged Exposure. 
* Articles included in the IPD analysis.   
 
 
Table 4.  






























































20 (33.9) LSAS 0 (0.0) 0 (0.0) 5 (25.0) - 











(48.7) - FAS 0 (0.0) 0 (0.0) - - 
Kampmann 











1 (5.0) 0 (0.0) 2 (10.) 1.00 








(50.0) - 30 (50.0) ATAQ 0 (0.0) - 2 (6.7) - 
De la Rosa 








7 (35.0) CAPS 0 (0.0) 0 (0.0) - - 
















13 (35.1) PDSS 0 (0.0) 0 (0.0) 1 (7.7) - 









13 (26.0) AI 1 (4.3) 0 (0.0) 2 (15.4) 0.82 









41 (32.0) AI 1 (2.0) 0 (0.0) 7 (17.1) 0.16 
Mühlberger 









(50.0) - FFS 0 (0.0) 0 (0.0) - - 
Mühlberger 










10 (21.3) FFS 2 (7.7) 1 (9.1) 3 (30.0) 0.4 
Moldovan 






(65.0) - 14 (35.0)
 LSAS AQ 
FASQ 





















(68.3) - FFS 1 (5.3) 4 (9.8) 0 (0.0) 0.54 






3.3. Risk of bias in the included studies 
As depicted in Figure 2, the quality of the included papers varied. Whereas the studies 
presented low methodological quality overall on randomization and blinding aspects, their 
high quality was observed in terms of attrition and reporting biases. The fact that only 
46.66% of the studies included a low risk of bias with regard to the random sequence 
generation and the blinding of participants and personnel, and only 20% of them followed 
an adequate allocation concealment, reveals the low methodological quality of the VR 
studies. Nevertheless, more troubling is the random sequence generation, which is often 
impossible to conduct in psychotherapeutic interventions. However, because the selection 
bias is mainly unclear, it is possible that proper randomizations were conducted and that a 
reporting bias is present instead. In any case, improvements within the field must be made 
in future studies. Finally, the fact that 21 datasets were irretrievable constitutes a possible 










3.4 Missing values and ceiling effects 
In all, 76 patients (9.4%) did not complete either the pre or post treatment assessments in 
the clinical trials that were included in the IPD meta-analysis, which is necessary to 
determine whether deterioration has occurred. However, examining these patients more 
closely did not reveal a relationship with any of the sociodemographic variables, χ2(1) = 
0.15-3.63, p = .06-.70. As for the predictors, 14 patients (1.7%) did not complete the pre-
treatment assessment, i.e., clinical severity. In addition, values were missing for 165 
patients (20.4%) in terms of marital status, 93 (11.5%) for educational level, and 19 
(2.4%) for age, but there were no missing values for gender (see Table 5). With regard to 











58 patients (7.2%) were identified as being close to reaching the ceiling of the self-report 
measures at the pre-treatment assessment, but these were still kept in the analysis of 
deterioration rates. However, as another way of determining their progress during 
treatment, an independent-samples t-test was performed post hoc on the available data 
for the ceiling-cases. Of the 51 patients who had both pre- and post-treatment data, there 
was a significant average decrease of 6.43 points (SD = 4.43), t(50) = 10.37, 95% CI [5.19, 
7.68], suggesting that they tended to improve during treatment.  
 
Table 5. 
Socio-demographic Characteristics of the Patients  
Baseline characteristic 
Virtual reality 
(n = 348) 
Other treatment 
(n = 282) 
Wait-list control 
(n = 180) 
Full sample 
(n = 810) 
Missing data 
Gender: n (% female) 248 (71.3) 203 (72.0) 99 (55.0) 550 (67.9) 0 (0.0) 
Age (years): M (SD) 35.6 (11.2) 36.6 (11.7) 36.9 (11.2) 36.2 (11.4) 19 (2.4) 
Marital status: n (%) 
    
165 (20.4) 
Single 135 (38.8) 125 (44.3) 65 (36.1) 325 (40.1) 
 
Relationship 138 (39.7) 115 (40.8) 67 (37.2) 320 (39.5) 
 
Highest educational 
level: n (%)     
93 (11.5) 
Primary school 20 (5.7) 8 (2.8) 7 (3.9) 35 (4.3) 
 
Secondary school 142 (40.8) 108 (38.3) 58 (32.2) 308 (38.0) 
 
University 149 (42.8) 134 (47.5) 91 (50.6) 374 (46.1) 
 
Employment: n (%) 
    
359 (44.3) 
Unemployed 18 (5.2) 28 (9.9) 15 (8.3)  61 (7.5) 
 
Student 35 (10.1) 28 (9.9) 13 (7.2) 76 (9.4) 
 
Employed 134 (38.5) 104 (36.9) 70 (38.9) 308 (38.0) 
 
Retired 2 (0.6) 3 (1.1) 1 (0.6) 6 (0.7) 
 
Primary diagnosis: n 
(%)     
2 (0.2) 
Social anxiety disorder 98 (28.2) 90 (31.9) 42 (23.3) 230 (28.4) 
 
Specific phobia 87 (25.0) 79 (28.0) 59 (32.8) 225 (27.8) 
 




33 (9.5) 25 (8.9) 22 (12.2) 80 (9.9) 
 
Panic disorder 3 (0.9) 1 (0.4) 2 (1.1) 6 (0.7) 
 
Panic disorder with 
agoraphobia 













3.5. Deterioration rates 
After dropping the 76 participants who did not complete either the pre or post treatment 
assessments, the remaining 734 (90.6%) were included in the investigation of 
deterioration in the IPD meta-analysis. From those 734 participants, 49 (6.0%) were 
identified as reliably deteriorated, i.e., with an RCI of at least 0.84. These numbers, 
however, varied between the conditions, ranging from 14 (4.0%) for patients receiving VR, 
8 (2.8%) when assigned to another form of treatment, and 27 (15.0%) in wait-list control 
(see Table 4). Given the large difference in rates, the two treatment conditions were 
combined and compared only to the waiting list, resulting in an OR = 4.87, 95% CI [2.69, 
8.80], indicating that the odds for deterioration were significantly higher for patients in 
wait-list control.  
Furthermore, the MH ORs were conducted for VR versus all controls on the one hand, all 
active treatments versus waitlist on the other hand, and finally VR versus active 
treatments to confirm no differences in odds of deterioration between these two 
conditions. With regard to the comparison of VR versus all controls, twelve of the 15 
studies were included in the comparison because 3 studies (Baños et al., 2011; De la Rosa 
& Cárdenas, 2012; Mühlberger et al., 2001) did not present deteriorated patients in any of 
the conditions, and, thus, it was not possible to establish the MH OR. As Figure 3 shows, 
the pooled OR was 0.61 (95% CI 0.31–1.23) in favor of VR, establishing that, on average, 
the VR-based treatments were 39% less likely to produce a deteriorated effect than all the 
control conditions. Nevertheless, the 95% confidence interval did not reach statistical 
significance (z=1.17, p=0.17). Heterogeneity between studies is low (Q(11) = 11.402, p = 
0.410, I2 = 3.525). While not significant, the odds ratio indicates that the odds of 
deterioration in VR are lower than in waitlist. Finally, Duval and Tweedie’s (2000) trim 
and fill method was used to identify any potentially missing studies and their impact on 
the summary MH odds ratio. Four potentially missing studies were identified, with an 
adjusted MH odds ratio of 0.98 [0.46 – 2.11]. 
 
Figure 3. Forest plot of included studies for the comparison VR versus all controls. 
 
Likewise, as figure 4 shows, the comparison of all active conditions (VR and other 
treatments) versus waiting list yielded an odds ratio of 0.165 [-3.879 – 0.411], p < 0.001 
Study name Statistics for each study MH odds ratio and 95% CI
MH odds Lower Upper Relative Relative 
ratio limit limit p-Value weight weight
Anderson et al., 2013 3.065 0.686 13.689 0.143 19.96
Botella et al., 2007 0.653 0.025 17.230 0.799 4.48
Botella et al., 2016 0.968 0.058 16.185 0.982 6.00
Bouchard et al., 2017 0.195 0.010 3.722 0.277 5.49
Difede et al., 2007 0.037 0.002 0.831 0.038 4.95
Kampmann et al., 2016 1.000 0.085 11.738 1.000 7.79
Moldovan et al., 2014 2.959 0.133 66.019 0.493 4.96
Muhlberger et al., 2003 0.354 0.058 2.159 0.260 14.06
North et al., 1996 0.187 0.009 4.062 0.286 5.05
Penate et al., 2014 0.568 0.048 6.703 0.653 7.76
Pitti et al., 2015 0.214 0.026 1.798 0.156 10.33
Tortella et al, 2011 0.514 0.053 4.937 0.564 9.18
0.612 0.304 1.231 0.169
0.01 0.1 1 10 100










reflecting that the odds of deterioration are significantly higher in waitlist compared to 
treatment (VR or other treatment). Although a higher variability between studies is 
noticeable in comparison to VR versus all controls, following the standards suggested in 
the literature (Higgins et al., 2003) the detected is also low (Q(9) = 11.343, p = 0.253, I2 = 
20.658). One potentially missing study was identified and imputed based on the Duval and 
Tweedie trim and fill method. The adjusted OR was 0.129 [0.049 – 0.346]. 
 
 
Figure 4. Forest plot of studies for the comparison all active conditions versus WL. 
 
 
Finally, a comparison of VR and active conditions was performed with the aim of 
confirming that no significant difference was present between these two conditions. The 
MH odds ratio comparing the odds of deterioration from VR to other treatment was 1.68 
[0.65 – 4.33], p = 0.287. Variability between studies was low (Q(6) = 2.64, p = 0.853, I2 = 
0.00). By doing this, the previous comparison of VR and other treatments versus WL is 
consistent.    
As for the specific clinical trials, Anderson et al. (2013) had the highest number of 
deteriorated patients in VR, 5 (13.9%), Tortella-Feliú et al. (2011) in another form of 
treatment, 4 (9.8%), and Difede et al. (2007) for wait-list control, 4 (50.0%). One of the 
worrisome aspects of utilizing RCI is the possibility of not identifying patients who 
deteriorated, due to the ceiling effects produced by the limitations of self-report measures 
(Martinovich, Saunders, & Howard, 1996). However, within this sample, only 58 (7.2%) 
were at risk of ceiling effects.  
 
3.6. Predictors of deterioration 
Given the large difference in deterioration rates, the analyses of potential predictors using 
logistic regressions were carried out separately for the three conditions. None of the 
predictors chosen a priori were related to deterioration in any of the cases; 1) clinical 
severity at pre-treatment assessment, 2) marital status, 3) educational level, 4) age, and 5) 
gender. The only exception was marital status in patients waiting for treatment, OR = 0.19, 
95% CI [0.05, 0.67], suggesting that being in a relationship lowered the odds of 
deterioration somewhat. See Table 6 for an overview of the predictors. 
  
Study name Statistics for each study MH odds ratio and 95% CI
MH odds Lower Upper 
ratio limit limit Z-Value p-Value
Anderson et al., 2013 0.897 0.100 8.069 -0.097 0.923
Bouchard et al. 2017 0.036 0.002 0.684 -2.212 0.027
Kampmann et al. 2016 0.231 0.020 2.713 -1.166 0.244
North et al., 1996 0.187 0.009 4.062 -1.068 0.286
Difede et al., 2007 0.018 0.001 0.445 -2.454 0.014
Botella et al., 2007 0.170 0.006 4.485 -1.061 0.289
Peñate et al. 2014 0.171 0.014 2.064 -1.389 0.165
Pitti et al. 2015 0.027 0.003 0.231 -3.294 0.001
Mühlberger et al. 2003 0.206 0.034 1.240 -1.726 0.084
Moldovan et al. 2014 2.959 0.133 66.019 0.685 0.493
0.165 0.067 0.411 -3.879 0.000
0.01 0.1 1 10 100











Table 6.  Odds Ratios for Each Predictor Variable Using the Full Imputed Model and Divided by 
Virtual Reality, Other Treatments, and Wait-list Control 
 
Virtual Reality Other treatments Wait-list control 
















Clinical severity at pre 
treatment assessment 
(lower severity) 




1.19 0.37 3.86 0.77 n.a. n.a. n.a. n.a. 0.19 0.05 0.67 
0.01
* 
Educational level, less 
than/at least university 
(less than university) 
0.64 0.18 2.26 0.49 n.a. n.a. n.a. n.a. 1.11 0.31 4.02 0.87 
Age (lower age) 1.01 0.96 1.07 0.63 1.25 0.98 1.60 0.08 1.04 0.98 1.10 0.16 
Gender (female) 2.13 0.63 7.17 0.22 n.a. n.a. n.a. n.a. 0.87 0.21 3.56 0.84 
Note. OR odds ratio; CI 95% confidence interval.  *p .05. n.a. = not applicable, i.e., too few 
cases for the logistic regression to converge 
 
4. Discussion 
The current study examined the deterioration rates of VR-based treatments for anxiety 
disorders. The dataset consisted of 15 studies, which, overall, were representative of the 
whole sample of 36 RCTs conducted within the field of VR for anxiety disorders and stress 
related disorders; each study had a sample of at least 10 patients in the VR condition. Raw 
scores from 810 patients were entered into an aggregated dataset, and the RCI was 
utilized to detect the deteriorated cases.  
First, it must be mentioned that, based on the results presented, overall, VR seems to be a 
non-deleterious treatment for patients with anxiety disorders. To the best of our 
knowledge, three previous studies have examined deterioration rates in technology-
mediated treatments conducted with patients who experienced an Internet intervention 
(Ebert, 2016; Karyotaki et al., 2018; Rozental et al., 2017), all of which did not show a 
larger deterioration in Internet conditions compared to active control groups. Hence, the 
present results constitute a novel finding in the same line as the cited Internet 
intervention studies. Taken together, all these studies permit to establish preliminary 
though solid evidence about the non-harmful effect of technology-mediated treatments. In 
this regard, the initial concerns about the potential negative impact of VR have been 
dissipated, at least with regard to exposure for anxiety disorders.    
Regarding the predictors, none of the included variables were related to higher or lower 
odds of deterioration, with the exception of marital status in the wait-list control. This 
result agrees with the existing IPD meta-analysis on deterioration rates for ICBT (Rozental 
et al., 2017).  However, because the total amount of deterioration was low, it was not 











dividing them between the three conditions made the predictor analysis lack sufficient 
power, even though the RCI of 0.84 was used, instead of 1.96, to determine deterioration.  
 
In the same vein, when ORs are compared, aggregated groups should be created due to the 
low frequencies. First, all the active conditions (VR and other active conditions) were 
compared to waiting list groups. This difference was statistically significant, showing that 
exposure, regardless of the type of treatment, is less likely to induce a deteriorated effect 
compared to patients assigned to waiting list controls. Nevertheless, when comparing VR 
versus all controls, no significant differences were found, although the tendency was in 
favor of VR. In all cases, the low frequencies of deterioration rates made it difficult to 
arrive at more conclusive statements.  
 
In fact, the pitfall of small samples within VR research has been previously described in 
the literature (Page & Coxon, 2016), and it is a major issue to overcome in attempting to 
increase the quality of research in the field and, thus, better determine the extent to which 
VR can be useful in clinical practice. A recent example acknowledging this issue is the trial 
conducted by Reger and colleagues (2016), which presented a large sample. Besides, due 
to reductions in VR equipment costs, an increase in the number of participants in studies 
might be expected (Lindner et al., 2017), even when this does not constitute the main cost 
of a treatment. Examples of low-cost devices implemented in RCT trials are now being 
conducted, which are expected to be a powerful alternative to expensive devices 
(Carlbring et al., 2018).  
 
4.1. Implications for research and practice 
First and foremost, there is an important implication with regard to the control groups.  Of 
the 36 studies that met the eligibility criteria to be included in the systematic review, 20 
used a waiting list group. Given the present results, due to ethical considerations, waiting 
lists should be carefully considered for use in future VR trials.  
 
Furthermore, new trials should assess and report negative effects, and patients suffering 
from deterioration or any other negative effect should be informed as an indispensable 
ethical requisite.  Hence, researchers should address the rising concern about the topic by 
conducting more studies on the topic, and clinicians implementing the guidelines in their 
routine practice.  
 
4.2. Limitations and Future Research   
If the total number of missing values was low, no imputation analyses were performed for 
missing values. However, this could have led to some biased results, and it would have 
been better to conduct these analyses. In addition, the lack of power due to the small 
samples in the VR literature hindered the ability to conduct regression analyses to 
determine predictors of deterioration. Thus, an important future study should build a 
more complete dataset in order to replicate the present study with a larger sample and 
apply more complex statistical analyses.  
 
Another important aspect is that establishing deterioration rates is a straightforward way 
to obtain a negative effect, but adverse effects may be present in many other forms that 
should also be examined. Furthermore, despite the results obtained, it cannot be 
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Pubmed string strategy 
((virtual reality) OR (virtual reality exposure therapy) OR ((virtual reality) AND (exposure))) 
AND ((anxiety disorder*) OR (obsessive compulsive disorder) OR (OCD) OR (general anxiety 
disorder) OR (GAD) OR (fear of falling) OR (arachnophobia) OR (post traumatic stress 
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